- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
N/A
N/A
N/A
N/A
NCT03906357
Incyte Corporation
Incyte Corporation
EXPANDED_ACCESS
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.
N/A
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2019-04-04 | N/A | 2022-04-11 |
2019-04-04 | N/A | 2022-04-19 |
2019-04-08 | N/A | 2022-04 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
Sexes Eligible for Study:
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
